Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
about
HER2 as a therapeutic target in head and neck squamous cell carcinomaThe AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptorEfficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparationProgesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.Spontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataEstrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeAntitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer modelNiche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imagingBiosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells.Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma.Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cellsSequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Tetraspecific ligand for tumor-targeted delivery of nanomaterials.Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleusHeparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancerCytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells.Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruptionMass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer modelsFlavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
P2860
Q27026178-888768E0-1AA4-4C35-BCA4-3DAFC3B97712Q27853383-9FFD4A56-5757-47F0-B7CE-594E88F0796AQ28485213-24EB56B3-AD87-4A26-9D6E-38D632A0BEAAQ28543361-EC972D8F-ADF1-48D7-8458-8075502EC242Q30009019-C350A0B5-4360-4FAC-B204-3AB40BBA9143Q30396530-BB90FDC7-6E4E-4AE0-9F13-1546C6653B7DQ30438089-2DCBC04E-02BD-4FDE-B5AE-40BB9C755F56Q33388617-95A6D38E-04F1-447B-A8E8-E62DD07102C7Q33561588-2629CF0B-D73B-49B2-B83B-4C7762B0C7E1Q33575434-ACEB81F9-ABC0-4DB6-825B-A5E3E71B5CEFQ33767497-A32E6274-141C-4F80-9F24-3CC714A9ADC1Q33861296-413B69A4-3081-49FC-B6D7-09ED2BE37997Q33921086-AC479141-ECB9-4815-BD9F-90B3FD1AC10AQ34060541-A5F33A98-BDD5-4A3E-8E86-0C4814373929Q34104067-058BD422-6835-4735-A91F-21F688DDCE91Q34117127-EF04A6B4-ED14-41EB-BEB6-0531FEAB501EQ34274373-29153AD7-6C3E-48F6-86E1-ED0491D7B7F6Q34363419-1C0B024B-1593-4768-BCCA-B403210CCF0AQ34380877-966D50CE-E8E5-4415-965F-02E55A7C63ADQ34433064-70028520-5973-43F9-8A31-6F875840565FQ34851586-36D7E264-E1FC-4D78-9E5B-9DBDC21BBFD4Q35023917-A0E3CE17-2F62-4143-923B-FF6C19933C1CQ35067562-6F381170-57EF-4276-B21F-D315893B4EC4Q35130286-DC39D1D4-5294-43EB-A67E-08DB8BB160D5Q35146597-221EB565-4D16-46A4-83EA-2E8F17168FBFQ35199371-9659D9C8-72FC-4FE4-BABB-C0C98A6C5AC6Q35287729-8E3856AF-65E5-4F22-9358-CFC7CAF8F943Q35546542-300D456A-71C1-41DD-833D-97FC2D3F76F6Q35565614-A2D6A9FB-A0EC-42AE-BBD9-00AB35A6E96CQ35743883-910C9C8C-A1A6-4080-A726-3A24B9757FEAQ35836035-29A384E8-839C-4C43-82CB-153DD5841CEEQ35845600-1E3DF32E-7D63-4D13-A88E-42B38D03C6ECQ35949779-59820D03-2938-4660-80AC-3BFCC3DE1DAAQ36166739-3037E079-9645-4550-80B0-3E66AFEC59B1Q36195594-DC4C8813-1C5E-4ED5-8A99-92F8BFE4F242Q36455404-6FE7AD00-839E-48B6-9FFD-7FCF14F02FDBQ36954809-1FC47398-7579-4988-9B9F-9B85D70FC6D6Q36983065-CDE018D9-C9E4-495A-92ED-DF0EE255EC63Q37013417-01D70717-9449-4BB0-9945-E0F335494813Q37061029-4AC78838-8204-4976-907D-41ECC812599D
P2860
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Assessment of epidermal growth ...... normal and tumour cell lines.
@en
type
label
Assessment of epidermal growth ...... normal and tumour cell lines.
@en
prefLabel
Assessment of epidermal growth ...... normal and tumour cell lines.
@en
P2093
P2860
P1433
P1476
Assessment of epidermal growth ...... normal and tumour cell lines.
@en
P2093
A-M Martin
B L Hudson-Curtis
C Arenas-Elliott
D W Rusnak
G M Spehar
K J Alligood
R J Mullin
S K Rudolph
T M Gilmer
P2860
P304
P356
10.1111/J.1365-2184.2007.00455.X
P577
2007-08-01T00:00:00Z